An NHS trust has agreed a three-year plan to cut up to £260m from its budget and break even. Under the plan, NHS Shropshire, ...

Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market ...

Apollo HealthCo clocked a revenue of ₹9,093 crore in FY25, growing 16% year-on-year. The platform delivered three successive ...

India is entering a new era of medical weight loss with the introduction of powerful drugs like Wegovy, and the growing off-label use of Ozempic and ...

The hot topic at Psychedelic Science Conference 2025 was the potential for treating PTSD with MDMA and magic mushrooms ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

India’s non-alcoholic beverage sector is projected to more than double to $88 billion by 2027. That’s a staggering 18% ...

India's clinical trial industry has surged into the top three globally, driven by regulatory reforms, affordability, vast ...

Wegovy, the ₹26K/month weight-loss jab, hits India with bold promises—from fat loss to heart health. But is this pharma fix a ...

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a fast-growing market.

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Mounjaro has released once-weekly injections that are helpful in managing type 2 diabetes along with showing remarkable ...